Lung Cancer Trials Ask AI to find trials
UnknownPhase 2NCT03944447
Official study title

Outcomes Mandate National Integration With Cannabis as Medicine

Study summary

This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedCannabis, Medical and RYAH-Medtech Inhaler

The study team can explain what participation involves.

Who it may be forChronic Pain · Chronic Pain Syndrome

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 2, 2022 · Source: ClinicalTrials.gov

Is enrollment open?Unknown

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?17 U.S. locations

Locations may change over time.

Who runs it?OMNI Medical Services, LLC

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2
Sponsor
OMNI Medical Services, LLC
Interventions being studied
Drug: Cannabis, Medical; Device: RYAH-Medtech Inhaler
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Clinical diagnosis of a Qualifying Condition for Medical Marijuana
  • Must be 18 years or older unless they have consent from their parent or legal guardian as defined under state law parameters
  • Must be willing to complete online surveys at baseline and the follow up points in this study
Reasons someone may not be able to joinExclusion criteria
  • Pregnancy
  • Breastfeeding
  • Inability to provide informed consent
  • Inability to complete study visits or questionnaires
  • Active suicidality or psychosis, that could be exacerbated by the administration of cannabis

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • OMNI Medical ServicesBoca Raton, Florida
  • OMNI Medical ServicesBradenton, Florida
  • OMNI Medical ServicesFort Lauderdale, Florida
  • OMNI Medical ServicesFort Myers, Florida
  • OMNI Medical ServicesGainesville, Florida
  • OMNI Medical ServicesMerritt Island, Florida
  • OMNI Medical ServicesMiami, Florida
  • OMNI Medical ServicesOcoee, Florida
  • OMNI Medical ServicesPensacola, Florida
  • OMNI Medical ServicesPompano Beach, Florida
  • OMNI Medical ServicesTampa, Florida
  • OMNI Medical ServicesWesley Chapel, Florida

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 2, 2022. Always confirm current availability with the study team.

View original record ↗